

Hospital &
Healthcare
Services



St. Lawrence

DOCKET NUMBER
PETITION RULE PRM 35-9
(54FR 38239)

348

December 6, 1989



Secretary of the Commission
U.S. Nuclear Regulatory Commission
Docketing and Service Branch, Docket # PRM-35-9
Washington, DC 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine physician and radiologist at St. Lawrence Hospital, Lansing, MI. I am deeply concerned over the revised 10 CFR 35 regulations governing the medical use of byproduct material as they significantly impact my practice of Nuclear Medicine and hinder me providing efficient low cost optimal care to individual patients.

For example, we now require two shipments of isotopes per day from our radiopharmaceutical supplier, Syncor International Corporation, which is located in Grand Rapids, MI. This requires additional cost which must be passed on to the patients. On week-ends and late evenings, Nuclear Medicine procedures are not available to the patients of our institution on an emergency basis due to the considerable cost. If we had a third shipment required for use on an emergency basis, the cost would be prohibitive in view of the infrequent requests for these examinations. When these examinations are needed, however, they would certainly benefit the patient greatly. Until this provision was adopted, we were able to use Technetium 99M Pertechnetate for a 24 hour period. Over the approximately 17 or 18 years that we used the previously acceptable 24 hour expiration date, no difficulties or adverse reactions to patients were encountered.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17 (a)(4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

1210 W. Saginaw □ Lansing, Michigan 48915 □ 517/372-3610
Division of Sisters of Mercy Health Corporation

8912180141 891206
PDR PRM
35-9

PDR

DSI


Secretary of the Commission
December 6, 1989
Page 2

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for rulemaking as expeditiously as possible.

Sincerely,



Stephen P. Wilensky, M.D.
Director of Nuclear Medicine

SPW/mc